Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease.

Jennifer I Lim; Christina J Flaxel; Laurie Labree

Return

Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease.

Author: Jennifer I LIM ¹ ; Christina J FLAXEL ; Laurie LABREE
Author Information

1. Doheny Retina Institute, Doheny Eye Institute and Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. jennifil@usc.edu
Publication Type:Case Reports
MeSH: Adult; Aged; Choroidal Neovascularization; drug therapy; etiology; Choroiditis; complications; Female; Humans; Male; Photochemotherapy; Photosensitizing Agents; therapeutic use; Porphyrins; therapeutic use
From:Annals of the Academy of Medicine, Singapore 2006;35(3):198-202
CountrySingapore
Language:English
Abstract:
INTRODUCTIONTo review the long-term outcome of photodynamic therapy (PDT) with verteporfin for inflammatory chorioretinal disease with subfoveal choroidal neovascularisation (CNV) over a 1-year period.
MATERIALS AND METHODSRetrospective review of eyes with subfoveal CNV for associated choroiditis that were treated with PDT using verteporfin over a 1-year period.
MAIN OUTCOME MEASUREvisual acuity.
RESULTSFive eyes in 4 patients, with diagnoses including serpiginous choroiditis (2), ocular histoplasmosis syndrome (OHS, 1), and punctate inner choroidopathy (PIC, 2) underwent standard treatment procedure for PDT with verteporfin. Visual acuity, fluorescein angiography and treatment parameters were reviewed. Follow-up ranged from 12 months to 36 months (median, 36 months). Pre-PDT visual acuities ranged from 20/60 to 20/400 (median, 20/200). Post-PDT visual acuities ranged from 20/30 to 20/400 at 1 year (median, 20/300). Visual acuity was stabilised (within 1 line) or improved (greater than 1 line) in 3 eyes at 1 year and 4 of the 5 eyes at last follow-up.
CONCLUSIONPDT for subfoveal CNV may stabilise, but rarely improves, visual acuity in eyes with choroidal neovascularisation secondary to inflammatory chorioretinal disease.